(Q38174251)

30 August 2017

title

Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir (English)

1 reference

30 August 2017

0 references

1 reference

2

Patrick Marcellin

1 reference

30 August 2017

Tarik Asselah

1

1 reference

30 August 2017

publication date

1 February 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

34 Suppl 1

1 reference

30 August 2017

page(s)

60-68

1 reference

Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.

30 August 2017

cites work

1 reference

Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.

21 January 2018

1 reference

Interferon free therapy with direct acting antivirals for HCV.

21 January 2018

1 reference

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.

21 January 2018

1 reference

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.

21 January 2018

1 reference

Faldaprevir and deleobuvir for HCV genotype 1 infection.

21 January 2018

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection

21 January 2018

1 reference

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

21 January 2018

1 reference

Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.

21 January 2018

1 reference

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.

21 January 2018

1 reference

Genomics and HCV infection: progression of fibrosis and treatment response

21 January 2018

1 reference

Exploratory study of oral combination antiviral therapy for hepatitis C.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12424

1 reference

30 August 2017

1 reference